Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
You may have heard about Descovy (des-ko'-vee), a medicine approved by the FDA in 2015. Descovy is approved to treat HIV. It can also help prevent people from getting HIV through sex. People with HIV have a virus that spreads in their body and damages the immune system, making it easier for them to get very sick from other infections. The two medicines contained in Descovy (emtricitabine and tenofovir alafenamide) work together with other medicines to stop the spread of HIV in your body.
The New England Journal of Medicine published the OASIS-4 trial in September 2025. This post is a journal club breaking down the OASIS-4 trial and what change it may bring to our clinical practice. Title: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity Citation: Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. N Engl J Med. 2025;393(11):1077-1087.
You may have heard about Symtuza, a medicine approved by the FDA in 2018 to treat people with HIV who have not been treated yet. It may also be used to replace another medicine for treating HIV in people whose condition is under control and whose infection is not resistant to Symtuza. Symtuza contains four medicines: cobicistat, darunavir, emtricitabine, and tenofovir alafenamide. These medicines have been used to treat HIV for many years.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
